By Heather Landi
Three big players in the kidney care market—Fresenius Health Partners, Cricket Health and InterWell Health—plan to form a new value-based care company. The deal, announced Monday morning, is valued at more than $2 billion, according to the companies.
read more
By Max Bayer
Two years since its inception, Volastra Therapeutics is partnering with Bristol Myers Squibb for up to three oncology targets focused on chromosomal instability, a deal that could exceed $1.1 billion should the assets hit milestones.
read more
By Andrea Park,Conor Hale
The medtech industry’s impressive venture funding activity was an anomaly in 2020, when most other sectors were floundering to stay afloat during the COVID-19 pandemic. A year later, as businesses around the globe returned to (somewhat) normal operations and overall VC activity hiked back up, medtech continued to ride that wave, coasting to its highest-ever annual funding total by the end of 2021.
read more
By Angus Liu
China's aggressive efforts to lower drug costs are unnerving some investors. But analysts at Jefferies argue the good days of growth are not over yet, projecting that the country's branded drug market could reach $85 billion in 2030.
read more
By Nick Paul Taylor
Immunogen’s full data on mirvetuximab soravtansine have underwhelmed investors. While the biotech is racing to the FDA with the results, its stock fell around 20% to below $5 in premarket trading after the release of survival data that fell short of investor expectations.
read more
By Andrea Park
The company’s V60 and V60 Plus ventilators for high-flow oxygen therapy have now sparked two separate Class I recalls since last summer.
read more
By Sharon Klahr Coey
On Tuesday, March 15, Equal Pay Day, Capital and Proxy Impact released the fifth Racial and Gender Pay Scorecard, and, surprise—women and people of color are still being paid less than their white male counterparts.
read more
By Robert King
HHS Secretary Xavier Becerra said the agency is looking into practices such as up-coding Medicare Advantage plans use to get overpayments from traditional Medicare, adding he doesn't want taxpayers to be "duped."
read more
By Kevin Dunleavy
England has conditionally approved Takeda’s Exkivity for non-small cell lung cancer patients whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations after chemotherapy and disease progression. In the rare form of the disease, Takeda is battling Johnson & Johnson's Rybrevant.
read more
By Nick Paul Taylor
Bavarian Nordic has found a taker for the Chinese rights to its RSV vaccine candidate. Nuance Pharma has taken the other side of the deal, handing over $12.5 million and committing to $212.5 million more in milestones to license the vaccine in China, South Korea and some other markets in Southeast Asia.
read more
By Andrea Park
Through the agreement, as Pear begins building the Japanese-language software, SoftBank will provide information about the Japanese market to help shape the technology. Once the software is ready for distribution, the Tokyo-based company will have the option to negotiate an exclusive licensing deal in the country.
read more
By Dave Muoio
Fierce Healthcare caught up with the CEO for a 2022 update on his company's shift from dialysis to kidney care, whether recent legal cases limit DaVita’s opportunities for growth and more.
read more
By Conor Hale
The system uses an artificial intelligence-powered ultrasound scanner to guide needles and catheter hardware, to help stem severe bleeding or deliver fluids and medications all while potentially in the back of an ambulance.
read more
By Angus Liu
Inspired by a natural mechanism to protect bacteria, bioengineers at Columbia University have developed a programmable “cloaking” system that could temporarily hide bacterial vehicles from the immune system to better deliver cancer therapies.
read more
By Ben Adams
It’s March, so it’s time for some #FierceMadness. We’re looking for the best of the best in drug names—and now it's time to get voting for your Sweet 16.
read more
